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Review
Lentiviral Vectors and Antiretroviral Intrinsic Immunity
BASTIEN MANGEAT and DIDIER TRONO
ABSTRACT
Multicellular organisms have evolved under relentless attacks from pathogens, and as a consequence have
spiked their genomes with numerous genes that serve to thwart these threats, notably through the building
of the innate and adaptive arms of the immune system. The innate immune system is by far the most ancient,
being found as widely as in plants and Drosophila, while adaptive immunity arose with the emergence of car-
tilaginous fishes. Innate immunity enters rapidly into the game during the course of an infection and gener-
ally involves the recognition by specific cellular receptors of common pathogen-associated patterns to elicit
broad defensive responses, mediated in humans by interferons, macrophages, and natural killer cells, amongst
others. When innate immunity fails to eradicate the infection quickly, adaptive immune responses enter into
play, to generate exquisitely specific defenses to virtually any pathogen, thanks to a quasi-infinite repertoire
of nonself receptors and effectors. A specific form of innate immunity, coined “intrinsic immunity,” completes
this protection by providing a constant, always-on, line of defense, generally through intracellular obstacles
to the replication of pathogens. This component of the immune system has gained much attention as it was
discovered that it is a cornerstone of the resistance of mammals against retroviruses. One of these newly dis-
covered intracellular molecular weapons, the APOBEC family of proteins, is active against several classes of
retroelements. We present here the current state of knowledge on this rapidly evolving field and discuss im-
plications for gene therapy.
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INTRINSIC IMMUNITY THROUGH 
“LETHAL EDITING”
EDITING IS A PROCESS by which genetic information is mod-ified through the enzymatic modification of nucleotides in
RNA or DNA. The discovery that editing enzymes were cru-
cial components of intrinsic immunity stemmed from the elu-
cidation of one of the most long-lasting puzzle of human im-
munodeficiency virus (HIV) research, namely the role of the
HIV Vif protein. After the cloning of the HIV-1 genome more
than 20 years ago, the functions of most of its nine genes were
rapidly identified. However, the role of Vif remained elusive,
a particularly vexing situation considering its absolute require-
ment for HIV-1 replication in vivo. It was rapidly recognized
that some “restrictive” cells, including macrophages and pri-
mary T cells, could not support replication of HIV-1 deleted
for the Vif gene, in contrast with many other cells, defined as
“permissive” (Gabuzda et al., 1992; von Schwedler et al.,
1993). Heterokaryon-based studies revealed that restrictive cells
contained an antiviral factor, the presence of which in producer
cells, rather than in target cells, was determinant (Madani and
Kabat, 1998; Simon et al., 1998). Through subtractive hy-
bridization studies between restrictive and permissive cells,
Malim and coworkers identified APOBEC3G (apolipoprotein
B mRNA-editing enzyme, catalytic polypeptide-like 3G), a
member of a large cytidine deaminase family, as being the cru-
cial antiviral factor (Sheehy et al., 2002). When present in the
producer cell, and in the absence of Vif, APOBEC3G is effi-
ciently packaged into budding virions, through a mechanism
that remains to be fully defined but that involves its binding to
the viral Gag protein (Cen et al., 2004; Svarovskaia et al., 2004).
The enzyme then stays associated with the reverse transcription
complex in the target cell, where it heavily deaminates cytidine
residues in the nascent single-stranded DNA reverse transcripts
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(Harris et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003;
Zhang et al., 2003). This is thought to have two consequences:
the uracil-containing DNA molecules are degraded, probably
through the intervention of DNA repair enzymes, while those
viral genomes that escape degradation are profoundly mutated
and fail to produce functional proteins, thereby halting further
viral spread (Fig. 1A). Facing this highly efficient attack in the
host cells, lentiviruses evolved a counterstrike. The vif gene
serves this role by connecting APOBEC3G to a Cul5-contain-
ing E3 ubiquitin ligase complex (Yu et al., 2003). This induces
the proteasome-mediated degradation of the cellular enzyme,
thus efficiently preventing its virion encapsidation (Mariani et
al., 2003; Sheehy et al., 2003).
Adding to its importance as an antiviral defense, APOBEC3G
antiviral activity is not limited to Vif HIV-1 but extends to a
broad range of wild-type lentiviruses naturally infecting non-
human hosts, such as simian immunodeficiency virus (SIV) and
equine infectious anemia virus (EIAV), and to more distantly
related retroviruses such as murine leukemia virus (MLV)
(Mangeat et al., 2003) and foamy viruses (Lochelt et al., 2005)
(Table 1). APOBEC3G-mediated DNA hypermutation there-
fore constitutes a barrier to the cross-species transmission of a
large array of retroviral pathogens.
The mode of action of the APOBEC family on single-
stranded reverse transcripts supported the notion that certain of
its members could also exert a detrimental action on the repli-
cation of other types of retroelements. Hepadnaviruses, such as
hepatitis B virus (HBV), were ideal candidates because they
also replicate their genome through the reverse transcription of
a pregenomic RNA into a double-stranded DNA molecule, a
process that takes place entirely in an intracytoplasmic viral
core before virion release. As suspected, APOBEC3G does af-
fect HBV replication through the inhibition of the accumula-
tion of reverse transcripts, although the deamination of HBV
DNA appears not to be essential (Turelli et al., 2004a) (Fig.
1B). Indeed, catalytically dead mutants of APOBEC3G affected
HBV replication as efficiently as the wild-type enzyme. The
precise antiviral mechanism at play against HBV still awaits
further investigation, although an inhibition of packaging of the
pregenomic RNA or destabilization of the reverse transcription
complex are possible explanations (Turelli et al., 2004a).
THE APOBEC FAMILY: AT THE EDGE OF
INNATE AND ADAPTIVE IMMUNITY
APOBEC3G is part of a cluster of related genes located 
on human chromosome 22, which comprises APOBEC3A to
APOBEC3H and is specifically found in primates (Jarmuz et
al., 2002) (Table 1). Other mammals such as mice or pigs con-
tain only the likely precursor of these genes, namely APOBEC3.
None of the putative nonantiviral physiological functions of the
APOBEC3 proteins is currently understood, but several of them,
in addition to APOBEC3G, have antiviral potential. APOBEC3F,
for instance, exhibits strong anti-HIV activity, countered by Vif
(Liddament et al., 2004; Wiegand et al., 2004; Zheng et al.,
2004). Accordingly, the pattern of mutations found in pro-
viruses isolated from AIDS patients matches not only the
APOBEC3G consensus target, but also the slightly different
pattern characteristic of APOBEC3F. In addition to the chro-
mosome 22 APOBEC3 cluster, the family also contains three
other genes, which are shared by all mammals and are expressed
in a narrowly tissue-specific manner: APOBEC1, AID, and
APOBEC2 (Table 1). Whereas the function of APOBEC2 is
unknown, APOBEC1 is known to be involved in the regulation
of lipid metabolism in small intestine enterocytes. There, it ed-
its a specific cytidine residue of the apolipoprotein B (ApoB)
mRNA into uridine, thus creating a stop codon that results in
the translation of a shorter ApoB protein (Wedekind et al.,
2003). Although this human enzyme is inactive against retro-
viruses, a report (Bishop et al., 2004) considerably broadens
the potential spectrum of APOBEC targets, with the demon-
stration that rat APOBEC1 can deaminate not only a retroviral
single-stranded DNA but also its genomic RNA precursor. The
other well-known member of the family is AID, a pillar of adap-
tive immunity as it is the factor responsible for both class switch
recombination (CSR) and somatic hypermutation (SHM) of im-
munoglobulin genes, two steps essential for antibody diversifi-
cation (Luo et al., 2004). No antiviral activity has been attrib-
uted so far to AID.
The APOBEC family thus comprises members crucial for
the adaptive and innate arms of immunity. This raises the in-
triguing possibility that a common APOBEC precursor, in-
volved in primitive intrinsic host protection against retroele-
ments, gave rise to a protein involved in antibody diversification
by refocusing its action from the pathogens DNA to the cellu-
lar immunoglobulin genes. This is supported by the finding that
AID, like APOBEC3 proteins, deaminates single-stranded,
rather than double-stranded, DNA targets (Chaudhuri et al.,
2003). The primitive pathogenic targets of the ancestral
APOBEC could have been retrotransposons, the ancestors of
modern retroviruses. These endogenous retroelements, which
comprise long interspersed nuclear elements (LINEs), short in-
terspersed nuclear elements (SINEs), and long terminal repeat
(LTR) retrotransposons and account for a massive total of about
40% of the human genome (International Human Genome Se-
quencing Consortium, 2001), could have constituted a danger
for host genome integrity through their random, and potentially
mutagenic, transposition. Although the genomes of endogenous
retroelements are usually silenced through methylation (Boeke
and Stoye, 1997), they nevertheless are thought to retrotrans-
pose in germ cells and during the genomic demethylation win-
dow that occurs in embryos at the preimplantation stage of de-
velopment. In face of this potential threat, it is striking that
several APOBEC3 proteins are highly active in vitro against di-
verse murine and even yeast retrotransposons and that the
mouse genome contains a high number of retrotransposon
proviruses that bear the scars of an APOBEC-mediated deam-
ination (Dutko et al., 2005; Esnault et al., 2005). The reported
expression of APOBEC3G and APOBEC3C in human germ
cells could therefore be related to such protective action (Neu-
berger et al., 2003). Furthermore, the fact that only LINEs and
SINEs are still active nowadays in the human genome is in good
accordance with the lack of susceptibility of at least some
LINEs to APOBEC3G action (Turelli et al., 2004b; Esnault et
al., 2005).
The expansion of the APOBEC3 group might have subse-
quently provided the host cells with a broader range of antiviral
mechanisms fighting different types of constantly diversifying
retroelements, including exogenous retroviruses and hepad-
MANGEAT AND TRONO914
naviruses. Accordingly, APOBEC3C, which is inactive against
HIV, has potent anti-SIV activity (Yu et al., 2004). In addition,
the fact that several members of the family underwent strong
positive selection, with an accelerated accumulation of non-
synonymous changes during their evolution, strongly suggests
that these proteins were involved in molecular conflicts, that is,
served as defense possibly against different types of retroviruses
(Sawyer et al., 2004; Zhang and Webb, 2004).
RETROELEMENTS AND THE APOBEC FAMILY 915
FIG. 1. The APOBEC family of proteins exerts its antiviral activity through several mechanisms. (A) APOBEC3G and
APOBEC3F are encapsidated into budding HIV-1 virions. They then stay associated with the reverse transcription complex in
the target cells, where they deaminate the viral DNA genome, halting further viral replication. (B) After the infection of a cell
by HBV, the partially double-stranded DNA viral genome is transported into the nucleus. Its subsequent repair by cellular en-
zyme leads to the expression of viral proteins. These govern the packaging of a pregenomic RNA into cytoplasmic cores and its
reverse transcription. The presence of APOBEC3G or APOBEC3F in these cells results in a marked drop in HBV reverse tran-
script accumulation, probably through the inhibition of assembly or destabilization of viral cores. (C) After entering resting CD4
T lymphocytes or monocytes, HIV-1 is blocked by APOBEC3G, which associates with a low molecular mass (LMM) complex
in these cells. On cellular activation, APOBEC3G relocalizes into a high molecular mass (HMM) complex, which relieves the
restriction.
THE COUNTERSTRIKE OF 
ASSAULTED VIRUSES
The potent antiretroviral mechanism of the APOBEC en-
zymes forced susceptible pathogens to develop adequate es-
capes. As stated previously, the lentiviral Vif proteins protect
their cognate genomes by provoking the clearance of APOBEC3G
from the viral producer cells. Yet, and in contrast to the broad
action of APOBEC3G, the viral protection conferred by Vif ap-
pears to be highly species specific. Indeed, HIV-1 Vif protein can
target the APOBEC3G protein from human (huAPOBEC3G)
and chimpanzee, but not the one from macaques or African
green monkeys (agmAPOBEC3G). Similarly, the Vif gene of
SIVagm, a widespread simian virus, is unable to counteract
huAPOBEC3G (Mariani et al., 2003). Interestingly, the species-
specific sensitivity of APOBEC3G to Vif action is governed by
a single amino acid at position 128 of APOBEC3G (Bogerd et
al., 2004; Mangeat et al., 2004; Schrofelbauer et al., 2004). In-
deed, HIV-1 Vif acts by binding huAPOBEC3G, an event blocked
when aspartic acid at position 128 of huAPOBEC3G is replaced
by the corresponding lysine found in agmAPOBEC3G. More-
over, this modified huAPOBEC3G acquires sensitivity to the
action of SIVagm Vif, and thus behaves just as agmAPOBEC3G
does.
Two important implications stem from this species-specific
action of Vif. First, the AIDS epidemics could arise only be-
cause SIVcpz and SIVmac, the viruses at the origin of HIV-1
and HIV-2, respectively, have vif genes that were able to coun-
teract huAPOBEC3G action. Second, a putative animal model
permitting HIV replication must possess an APOBEC3G that
is susceptible to HIV-1 Vif.
Although the vif gene of lentiviruses efficiently fends off the
APOBEC attack, other retroviruses have evolved other escape
mechanisms. One example is the bet gene of foamy viruses
(Lochelt et al., 2005). In addition, MLV, which replicates in
murine APOBEC3-positive cells but does not have either a vif
or a bet gene, survives because its Gag protein fails to be rec-
ognized by the murine deaminase, which is therefore excluded
from released virions (Kobayashi et al., 2004; Doehle et al.,
2005). Why MLV evolved such a simple escape mechanism
while HIV and foamy viruses had to develop brand new genes
to achieve the same goal is an intriguing question. The lentivirus
EIAV, which is also devoid of a known counterstrike protein
but is sensitive to human APOBEC3G, might also have devel-
oped its own mechanism to escape the action of the equine or-
tholog of APOBEC3. This might involve its selective replica-
tion in cells devoid of this enzyme, the presence in one of its
proteins of a hidden Vif-like activity, or a twist that renders its
Gag protein invisible to the deaminase.
IMPLICATIONS FOR LENTIVECTOR
PRODUCTION
The presence in human cells of such a powerful antiretrovi-
ral mechanism has important implications for gene therapy. In-
deed, even minute amounts of a harmful APOBEC protein in
producer cells will undermine the successful use of retroviruses
as a gene delivery system, through a decrease in virion infec-
tivity and an increase of the proportion of defective particles,
which favors the appearance of toxic effects and immune re-
sponses directed against virion components. Laboratories work-
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TABLE 1. CHARACTERISTICS OF HUMAN AND RODENT APOBEC FAMILY OF CYTIDINE DEAMINASESa
HIV-1 Vif
HIV-1 SIV MLV HBV sensitivity
Human
APOBEC1  ND  ND ND
APOBEC2   ND ND ND
AID    ND ND
APOBEC3A  ND  ND ND
APOBEC3B /  / ND 
APOBEC3C    ND 
APOBEC3D ND ND ND ND ND
APOBEC3E ND ND ND ND ND
APOBEC3DE ND ND ND ND ND
APOBEC3F     /
APOBEC3G     
APOBEC3H ND ND ND ND ND
Rodent
APOBEC1 rat:  ND  ND 
mouse: 
APOBEC2  ND ND ND ND
AID ND ND ND ND ND
APOBEC3    ND 
Abbreviation: ND, not determined.
aThe antiviral activity against different retroelements and the sensitivity to HIV-1 Vif are listed for each enzyme.
Antiviral activity
ing with specific vector systems, such as EIAV or SIV, would
benefit from defining the susceptibility of their vectors to all
APOBEC family members and from choosing producer cells
devoid of any traces of relevant APOBEC activity.
In addition, some transgenes might activate the expression
of a detrimental APOBEC in producer cells. The expression of
APOBEC family members should therefore be checked when
the production of high-titer vectors is proving difficult. Like-
wise, when a transgene fails to be expressed or to demonstrate
correct effector functions despite adequate proviral DNA titer,
the polymerase chain reaction (PCR) amplification of the pro-
viruses in target cells might reveal the presence of APOBEC-
induced mutations potentially altering either promoter or cod-
ing sequences.
It would thus be beneficial to obtain a packaging system in-
sensitive to human APOBEC inhibition, even in the absence of
the viral vif gene. In this respect, much might be learned from
the escape mechanisms of different retroviruses.
APOBEC3G IN TARGET CELLS CAN ALSO
BLOCK LENTIVECTOR TRANSDUCTION
Resting CD4 cells are notorious for being resistant to HIV
infection or lentivector transduction, imposing a block at an
early postentry stage of viral replication (Zack et al., 1990; Ko-
rin and Zack, 1998; Ducrey-Rundquist et al., 2002). Because
these cells constitute the vast majority of T cells in vivo, their
targeting for lentivector-mediated gene treatment of immuno-
deficiencies or other diseases is complex. Light was shed on
this problem when it was discovered that APOBEC3G not only
is the antiviral factor counteracted by Vif in producer cells, but
is also responsible for this target cell resistance (Chiu et al.,
2005) (Fig. 1C). In resting T cells and monocytes, APOBEC3G
resides in a low molecular mass (LMM) complex as opposed
to the high molecular mass (HMM) complex in which it is found
in activated T cells, macrophages, and other cells. This LMM
APOBEC3G is responsible for the replication block through an
undefined mechanism, which probably involves recruitment of
the deaminase to the reverse transcription complex. Activating
the CD4 T cells relocalizes APOBEC3G into the high mo-
lecular mass (HMM) complex and relieves the restriction. The
design of putative HIV vectors capable of escaping this block-
ade will require the fine deciphering of its mechanism.
In addition to resting T cells, this complex might also be re-
sponsible for the low susceptibility of other cell types to trans-
duction, be they of hematopoietic origin or otherwise. In this
respect, it could be envisioned that murine APOBEC3, which
is expressed in mouse gonads, could account for the block that
murine oocytes impose to lentivectors during their first divi-
sions (our unpublished data). Finally, it will be crucial to de-
termine whether other APOBEC family members also are en-
dowed with the ability to mediate such a mode of resistance.
CYTIDINE DEAMINASE AS A GENE-BASED
ANTIVIRAL THERAPY
On the basis of the strong antiviral activity of APOBEC fam-
ily members, it is tempting to propose their use for the gene
therapy of several infectious diseases. Two potential approaches
can be envisioned for the use of APOBEC3G as a tool to fight
HIV-1 infection. These would take advantage of the antiviral
action mediated by the APOBEC3G residing in either the pro-
ducer or the target cells.
Producer cells
The ex vivo transduction of patients’ hematopoietic stem cells
(HSCs) with a Vif-resistant APOBEC3G, followed by their
reinjection, would provide the host with a pool of lymphocytes
incapable of sustaining productive HIV replication. Although
this approach will probably be efficient only if a large per-
centage of blood cells can be reconstituted by the transgenic
precursors, it is hoped that this would slow down the infection
and permit the amount of antiviral drugs administered to the
patient to be reduced. The safety of this approach will never-
theless need to be carefully investigated. The alteration applied
to human APOBEC3G to render it Vif resistant might indeed
alter putative regulatory circuitries, potentially leading to ran-
dom mutagenic deamination of the host genome. Arguing
against this possibility, however, are African green monkeys
that possess an HIV Vif-resistant APOBEC3G but are not es-
pecially prone to leukemia, raising hopes that the same will hold
true in humans. In any case, using the HIV-1 LTR to drive the
expression of the Vif-resistant APOBEC3G could solve the
problem. In this situation, the potentially harmful enzyme would
indeed be expressed only in infected cells, and only during the
few days during which they can survive with the virus, thus
minimizing exposure to dysregulated genomic deamination.
Alternatively, lentivectors expressing a small hairpin RNA
(shRNA) against Cul5 under the control of the HIV-1 LTR
might be introduced into HSCs. The advantage of this approach
over conventional drug-based treatments is that viral resistances
would certainly occur less frequently, because Vif would have
to evolve a new mechanism of action.
Target cells
The transduction of blood precursors with a putative mutant
of APOBEC3G constitutively residing in the LMM complex,
even upon T cell stimulation, would provide the cells with two
APOBEC3G pools: the endogenous APOBEC3G, which would
perform its putative physiological role, and the “LMM-resident”
transgenic APOBEC3G, which would fight incoming viruses.
Interestingly, the earliness of the step of infection at which the
viruses would be blocked, before integration into the host ge-
nome, would hopefully allow for the preservation of enough
uninfected T cells to maintain an effective immune system. Al-
though this approach might prove dangerous if the LMM form
of APOBEC3G is more prone to induce deleterious nucleotide
deaminations in the host genome in dividing cells than its HMM
counterpart (Chiu et al., 2005). The problem could be tackled
if a catalytically inactive APOBEC3G could also mediate the
block, a likely possibility because hypermutations do not seem
to be involved in the restriction. Along the same line of thought,
drugs locking APOBEC3G in the LMM complex could also in-
duce an early intracellular resistance to retroviral infections, al-
though they would also probably impede the putative physio-
logical function of the enzyme.
To gain insights into the efficiency and safety of these dif-
ferent approaches, the variously modified APOBEC3Gs could
be introduced into mice reconstituted with a human immune
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system (Traggiai et al., 2004), provided these prove able to sus-
tain a productive HIV-1 infection.
These novel gene therapy approaches could stand as valu-
able alternatives, or supports, to current drug treatments, the ef-
ficiency of which is steadily ebbing as a result of resistance in
a growing percentage of patients. It is therefore not surprising
that the first human lentivector gene therapy trial, which is cur-
rently being evaluated in phase I clinical trials, is aimed at treat-
ing human HIV infection through the introduction into T cells
of an HIV resistance gene (Humeau et al., 2004; Lu et al., 2004).
APOBEC FAMILY AS AN ANTI-HBV THERAPY
The chronic hepatitis resulting from HBV infection can be
treated with lamivudine or interferon- (IFN-). However, re-
sistant HBV clones often emerge during long-term lamivudine
treatment, and IFN treatment is associated with severe side ef-
fects such as autoimmune disease and bone marrow reduction
(Hollinger and Liang, 2001). Therefore, great efforts are being
made to develop better treatments against this major cause of
mortality and morbidity, amongst which gene therapy holds
some promise (Xu et al., 2003).
Human hepatocytes do not express APOBEC3G or
APOBEC3F, at least under normal circumstances. It can thus
be envisioned that patients’ liver may be rendered resistant to
HBV through the adeno-associated viral or lentiviral vector-
mediated delivery of APOBEC3G into their hepatocytes. Ow-
ing to the independence of APOBEC3G anti-HBV activity from
deamination, hepatocytes expressing a catalytically inactive
form of the enzyme would be endowed with a safe mechanism
to fight the infection.
The “APOBEC3G gene therapy” approach is interesting be-
cause it might actually recapitulate a bona fide defense occur-
ring in hepatocytes in certain situations in vivo. It has, for in-
stance, been shown that HBV DNA is cleared from infected
hepatocytes during acute infection through an unidentified in-
tracellular mechanism (Guidotti et al., 1999). The fact that this
protection seems induced by cytokines in vivo and by IFN in
culture raises the possibility that an APOBEC family member
might be upregulated in hepatocytes subsequent to these treat-
ments to mediate HBV clearance. In this respect, it is worth
noting that APOBEC3A is much upregulated in peripheral
blood mononuclear cells (PBMCs) on IFN- treatment (Taylor
et al., 2004). In addition, the occasional G-to-A hypermutant
HBV clones that have been detected in patients might consti-
tute by-products of the anti-HBV action of an APOBEC fam-
ily member.
It will be interesting to determine precisely whether other
APOBECs are active against HBV, and whether any of them
is constitutively expressed in hepatocytes or can be upregulated
by inflammation, HBV infection, or pharmacological treatment.
APOBEC FAMILY INVOLVEMENT IN
CANCERS
One of the most frequent genomic point mutations, the C-
to-T transition, arises through the deamination of cytidines into
uridines (Lodish, 2003). Moreover, about 23% of mutations in
hereditary human diseases and 24% of mutations in p53 in hu-
man cancers are G-to-A transitions (Waters and Swann, 2000).
It has also been noted that the base pair context of mutation in
different oncogenes or tumor suppressors vary between cell
types (Beale et al., 2004). It can thus be argued that what are
currently considered to be “spontaneous mutations” could ac-
tually reflect the action of upregulated, dysregulated, or ec-
topically expressed APOBEC enzymes. Accordingly, the ex-
pression of APOBEC family members has been demonstrated
in many cancerous cells (Jarmuz et al., 2002), certain leukemic
B cells show hallmarks of uncontrolled AID-mediated hyper-
mutation in oncogenes, and the APC gene in colorectal tumors
harbors a pattern of mutations compatible with APOBEC1 edit-
ing (Beale et al., 2004). Finally, APOBEC1 transgenic expres-
sion in liver leads to cancer in mice (Yamanaka et al., 1995).
Within the context of a precancerous tissue, cytidine deamina-
tion could therefore provide a continuous source of potentially
oncogenic mutations, in a stepwise progression toward metas-
tasis development. Therefore, whether the presence of an up-
regulated APOBEC could serve as a prognostic tool for the ag-
gressiveness of the tumor is worth further investigation.
But most importantly, the inherent danger residing in the ec-
topic delivery of these deaminases in cells might preclude their
future use as safe molecular tools for gene-based therapies.
PERSPECTIVES
We have focused this review on the action of the APOBEC
family against retroelements. However, other viral families
might be affected, as well as their related gene delivery sys-
tems. For instance, vaccinia vectors, which replicate their DNA
in the cytoplasm, where APOBEC3G is located, can efficiently
transduce monocytes, B cells, and natural killer cells, but not
T lymphocytes (Sanchez-Puig et al., 2004). The perspective that
APOBEC3G might be responsible for this blockade paves the
way for further provocative and stimulating research.
Although APOBEC3G and several other APOBEC family
members provide antiretroviral protection, it is probable that
mammalian cells contain many other unrecognized intrinsic
antiviral effectors. The newly discovered Trim5-mediated block
to retroviral infection constitutes one such example. Identify-
ing these factors and unraveling their mode of action will cer-
tainly lead to advances in gene therapy and, in more general
terms, in molecular virology.
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